余细勇，医学博士，香港大学和美国贝勒医学院博士后，二级教授，硕士生和博士生导师，博士后合作导师。

行政职务：广州医科大学药学院院长、广州分子与临床药理学研究所所长，广州医科大学临床药学系主任。同时兼任国家药监局重点实验室主任、广东省重点实验室主任、广州市重点实验室主任、广东省高校重点实验室主任、粤港澳高校联合实验室主任。

研究方向：聚焦心肺重大疾病整合防治的新药研发，开展表观遗传药理学、分子临床药理学、分子药剂生物学研究。

社会职务：现任中国药理学会副理事长、中国药理学会表观遗传药理学专业委员会主任委员、中国药理学会临床药理专业委员会和心血管专业委员会常委。国际肿瘤心脏病学会（IC-OS）理事，国际心脏研究会（ISHR）中国转化医学工作委员会名誉主任委员，美国基因与细胞治疗学会官方杂志Molecular Therapy（IF12.1）的副主编；广东省药理学会理事长/监事长，广东省药品监管科学学会副会长。中国药学会药学教育专业委员会委员、广东省药学教指委副主任委员。

学术成果：发表学术论文近600篇（其中SCI论文260篇，IF>10的论文80多篇)，被引近1.5万次，H指数56。主编学术专著4部、主编副主编教材3部。先后主持国家自然科学基金重点项目3项、国家973项目1项、国家重点研发计划1项（首席）。申请并获得授权国内外（含欧美等国家）发明专利40多项，牵头创办药学院科技成果转化平台1个。主持获得省部级科技成果一等奖2项、二等奖3项，医学科学奖5项，瑞士日内瓦国际发明金奖1项，美国硅谷国际发明银奖1项，英国伦敦国际发明金奖1项，华夏医学科技奖1项，中国产学研合作创新成果奖1项。2个国家一流专业和2门国家一流课程负责人。连续多年入选Stanford-Elservier药学全球前2%顶尖科学家榜，以及ESI多学科全球前2%顶尖科学家榜单。

所获荣誉：国务院政府特殊津贴专家，国家心血管专家委员会委员，中国工程院战略咨询专家，国家药监局CDE评审专家。俄罗斯工程院（RAE）外籍院士、欧洲自然科学院(EANS)院士。广东省卫生系统“五个一科教兴医工程”学术与技术带头人，第八届广东省丁颖科技奖，南粤优秀教育工作者，广州医科大学黄大年式教师团队负责人，广州最美科技工作者。

2020年以来发表的代表论文：

1. Li J, Yi H, Fu Y, Zhuang J, Zhan Z, Guo L, Zheng J, Yu XY*, Zhang DY*. Biodegradable iridium coordinated nanodrugs potentiate photodynamic therapy and immunotherapy of lung cancer. J Colloid Interface Sci. 2025 Feb 15; 680(Pt A):9-24. （IF9.4，中科院一区，通讯作者）

2. Wang Y, Wu W, Xu Y, Wu C, Han Q, Lu T, Zhang H, Jiao L, Zhang Y, Liu B, Yu XY*, Li Y*. Ncl liquid-liquid phase separation and SUMOylation mediate the stabilization of HIF-1α expression and promote pyroptosis in ischemic hindlimb. Biochim Biophys Acta Mol Basis Dis. 2025 Feb 10;1871(4):167706. （IF6.2，中科院二区，通讯作者）

3. Liu Z, Wu J, Luo Z, Hou Y, Xuan L, Xiao C, Chang J, Zhang D, Zheng G, Guo J, Tang G*, Yu XY*. 3D Biofabrication of Microporous Hydrogels for Tissue Engineering. Adv Healthc Mater. 2025 Jan; 14(3):e2403583. （IF10.0，中科院一区，通讯作者）

4. Zheng Q, Liu Y, Guo M, Zhang X, Zhang Q, Yu XY*, Lin Z*. Discovery of therapeutic targets in cardiovascular diseases using high-throughput chromosome conformation capture (Hi-C). Front Genet. 2025 Mar 13;16:1515010. doi: 10.3389/fgene.2025.1515010. （IF2.8，中科院二区，通讯作者）

5. Xu TT, Deng YY, Yu XY*, Li M*, Fu YY*.  Natural autophagy modulators in non-communicable diseases: from autophagy mechanisms to therapeutic potential. Acta Pharmacol Sin. 2025 Jan;46(1):8-32.（IF6.9，中科院一区，通讯作者）

6. Huang P, Wu G, Huang M, Deng Y, Chen X, Ye G, Yu XY, Wang H, Wen H*, Zhou Y*. Copper-coordinated nanomedicine for the concurrent treatment of lung cancer through the induction of cuproptosis and apoptosis. Eur J Pharm Sci. 2025 Jan 1;204:106942. （IF4.4，中科院二区）

7. Wang H, Lin S, Xie J, Chen X, Deng Y, Huang P, Peng K, Gao W, Ye G, Wang G, Yu XY, Wen H, Qin L, Zhou Y. Chondroitin sulfate nanoparticles based on co-delivery dual drug induced ferroptosis in lung cancer cells by disrupting mitochondrial oxidative homeostasis. Mater Today Bio. 2025 Mar 5;31:101632. doi: 10.1016/j.mtbio.2025.101632. （IF8.7，中科院二区）

8. Xu W, Zheng C, Chen M, Deng X, Zhang L, Lei X, Liang L, Yu XY, Hu X, He J, Lin S, Ruan Z. Modular Synthesis of Bioactive Selenoheterocycles for Efficient Cancer Therapy via Electrochemical Selenylation/Cyclization. J Med Chem. 2025 Mar 27;68(6):6339-6360. doi: 10.1021/acs.jmedchem.4c02724. （IF6.8，中科院二区）

9. Zheng C, Chen F, Yang F, Li Z, Yi W, Chen G, Li T, Yu XY*, Chen X*. Myocardial cell mitochondria-targeted mesoporous polydopamine nanoparticles eliminate inflammatory damage in cardiovascular disease. Int J Biol Macromol. 2024 Dec;282(Pt 5):137141. doi: 10.1016/j.ijbiomac.2024.137141. （IF7.7，中科院一区，通讯作者）

10. Li Y#, Liu Y#, Yu XY#, Xu Y#, Pan X, Sun Y, Wang Y, Song YH, Shen Z. Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications. Signal Transduct Target Ther. 2024 Nov 18;9(1):305. doi: 10.1038/s41392-024-02013-w. （IF40.8，中科院一区，并列第一作者）

11. Qin YY, Yu H, Huang Y, Yang X, Li S, Shen A, Lin Y, Zhang M, Zhu Q, Zhang J, Zhang L*, Yu XY*. Naked Gene Delivery Induces Autophagy for Effective Treatment of Acute Lung Injury in a Mouse Model. Int J Nanomedicine. 2024 Oct 24; 19:10801-10818. doi: 10.2147/IJN.S477947. （IF6.6，中科院二区，通讯作者）

12. Chen X, Huang Y, Yang S, Wang S, Chen L, Yu XY*, Gan N*, Huang S*. In-situ nanozyme catalytic amplification coupled with a universal antibody orientation strategy based electrochemical immunosensor for AD-related biomarker. Biosens Bioelectron. 2024 Dec 15;266:116738. doi: 10.1016/j.bios.2024.116738. （IF10.7，中科院一区，通讯作者）

13. Yang X, Lin G, Chen Y, Lei X, Ou Y, Yan Y, Wu R, Yang J, Luo Y, Zhao L, Zhang X, Yang Z, Qin A, Sun P, Yu XY*, Hu W*. Chlorquinaldol Alleviates Lung Fibrosis in Mice by Inhibiting Fibroblast Activation through Targeting Methionine Synthase Reductase. ACS Cent Sci. 2024 Aug 28;10(9):1789-1802. doi: 10.1021/ acscentsci.4c00798. （IF12.7，中科院一区，通讯作者）

14. Zhao LX, Zhu YG, Tao H, Chen XY, Yin F, Zhang YY, Qin JF, Huang YY, Cai BK, Lin YH, Wu Zhang Y, Liang L, Shen A*, Yu XY*. Ailanthone ameliorates pulmonary fibrosis by suppressing JUN-dependent MEOX1 activation. Acta Pharm Sin B, 2024;14(8):3543-3560.（IF14.7，中科院一区，通讯作者）

15. Liang L, Peng W, Qin A, Zhang J, Chen R, Zhou D, Zhang X, Zhou N, Yu XY*, Zhang L*. Intracellularly synthesized artificial exosome treats acute lung injury. ACS Nano. 2024 Aug 13;18(32):21009-21023. doi: 10.1021/acsnano.4c01900.（IF15.8，中科院一区，通讯作者）

16. Wang Y, Tu J, Wu W, Xu Y, Li Y, Pan X, Liu B, Lu T, Han Q, Zhang H, Jiao L, Zhang Y, Yu XY, Shen Z, Li Y. The orchestration of cell-cycle reentry and ribosome biogenesis network is critical for cardiac repair. Theranostics. 2024 Jun 24;14(10):3927-3944. doi: 10.7150/thno.96460. （IF12.4，中科院一区）

17. Wu Y, Li J, Zhu L, Wang D, Song J, Yu XY, Li Y, Tang BZ. Photosensitive AIEgens sensitize bacteria to oxidative damage and modulate the inflammatory responses of macrophages to salvage the photodynamic therapy against MRSA. Biomaterials. 2024 Sep;309:122583. doi: 10.1016/j.biomaterials.2024.122583. （IF12.8，中科院一区）

18. Yang C, Ge L, Yu XY, Lazarovici P, Zheng W. Artemisinin Confers Cytoprotection toward Hydrogen Peroxide-Induced Cell Apoptosis in Retinal Pigment Epithelial Cells in Correlation with the Increased Acetylation of Histone H4 at Lysine 8. Molecules. 2024 Apr 15;29(8):1789. doi: 10.3390/molecules29081789. （IF4.1，中科院二区）

19. Lei X, Li Z, Huang M, Huang L, Huang Y, Lv S, Zhang W, Chen Z, Ke Y, Li S, Chen J, Yang X, Deng Q, Liu J, Yu XY#. Gli1-mediated tumor cell-derived bFGF promotes tumor angiogenesis and pericyte coverage in non-small cell lung cancer. J Exp Clin Cancer Res. 2024 Mar 16;43(1):83. doi: 10.1186/s13046-024-03003-0. （IF11.3，中科院一区，通讯作者）

20. Xiao YY, Xia LX, Jiang WJ, Qin JF, Zhao LX, Li Z, Huang LJ, Li KX, Yu PJ, Wei L, Jiang XY, Chen ZS, Yu XY#. Cardiopulmonary progenitors facilitate cardiac repair via exosomal transfer of miR-27b-3p targeting the SIK1-CREB1 axis. Cell Prolif. 2024 May;57(5):e13593. doi: 10.1111/cpr.13593. （IF5.9，中科院一区，通讯作者）

21. Xia LX, Xiao YY, Jiang WJ, Yang XY, Tao H, Mandukhail SR, Qin JF, Pan QR, Zhu YG, Zhao LX, Huang LJ, Li Z, Yu XY#. Exosomes derived from induced cardiopulmonary progenitor cells alleviate acute lung injury in mice. Acta Pharmacol Sin. 2024 Aug; 45(8):1644-1659. doi: 10.1038/s41401-024-01253-4. （IF6.9，中科院一区，通讯作者）

22. Wu Q, Liu WJ, Ma XY, Chang JS, Zhao XY, Liu YH, Yu XY#. Zonisamide attenuates pressure overload-induced myocardial hypertrophy in mice through proteasome inhibition. Acta Pharmacol Sin. 2024 Apr;45(4):738-750. doi: 10.1038/s41401-023-01191-7. （IF6.9，中科院一区，通讯作者）

23. Cen H, Sun M, Zheng B, Peng W, Wen Q, Lin Z, Zhang X, Zhou N, Zhu G, Yu XY#, Zhang L#, Liang L#. Hyaluronic acid modified nanocarriers for aerosolized delivery of verteporfin in the treatment of acute lung injury. Int J Biol Macromol. 2024 Apr 4:131386. doi: 10.1016/j.ijbiomac.2024.131386. （IF7.7，中科院一区，通讯作者）

24. Li KX, Li JR, Zuo SJ, Li X, Chen XT, Xiao PY, Li HT, Sun L, Qian T, Zhang HM, Zhu D, Yu XY#, Chen G#, Jiang XY#. Identification of miR-20b-5p as an inhibitory regulator in cardiac differentiation via TET2 and DNA hydroxymethylation. Clin Epigenetics. 2024 Mar 15;16(1):42. doi: 10.1186/s13148-024-01653-7. （IF4.8，中科院二区，通讯作者）

25. Zhao LP, Zheng RR, Rao XN, Huang CY, Zhou HY, Yu XY, Jiang XY, Li SY. Chemotherapy-Enabled Colorectal Cancer Immunotherapy of Self-Delivery Nano-PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance. Adv Sci (Weinh). 2024 Jan 18:e2309204. doi: 10.1002/advs.202309204. （IF14.3，中科院一区，通讯作者）

26. Yang C, Rubin L, Yu XY, Lazarovici P, Zheng W. Preclinical evidence using synthetic compounds and natural products indicates that AMPK represents a potential pharmacological target for the therapy of pulmonary diseases. Med Res Rev. 2024 May;44(3):1326-1369. doi: 10.1002/med.22014. （IF10.9，中科院一区）

27. Zheng Y, Yi H, Zhan Z, Xue SS, Tang G*, Yu XY*, Zhang DY*. Reactive oxygen/nitrogen species scavenging and inflammatory regulation by renal-targeted bio-inspired rhodium nanozymes for acute kidney injury theranostics. J Colloid Interface Sci. 2024 May 15;662:413-425. doi:10.1016/j.jcis.2024.02.054. （IF9.4，中科院一区，通讯作者）

28. Wang Y, Tan WY, Li XY, Zhang XJ, Chen CY, Wu XY, and Yu XY*. Effect of m6A Methylation Modification on IncRNA ENST00000425005 in Doxorubicin Resistance and Epithelial-Mesenchymal Transition Progression in Lung Cancer Cells.  J. Biomed. Nanotechnol. 2024; 20(1):1–10. （IF2.3，中科院四区，通讯作者）

29. Wu Y, Chen X, Zhu L, Wang D, Li X, Song J, Wang D, Yu XY, Li Y, Tang BZ. Endoplasmic Reticulum-Targeted Aggregation-Induced Emission Luminogen for Synergetic Tumor Ablation with Glibenclamide. ACS Appl Mater Interfaces. 2023 Oct 30. doi: 10.1021/acsami.3c10940. （IF8.3，中科院二区）

30. Wu Q, Zou S, Liu W, Liang M, Chen Y, Chang J, Liu Y, Yu XY#. A novel onco-cardiological mouse model of lung cancer-induced cardiac dysfunction and its application in identifying potential roles of tRNA-derived small RNAs. Biomed Pharmacother. 2023; 165:115117. （IF6.9，中科院一区，通讯作者）

31. Zhou Z, Gu Y, Wu LX, Wang Y, Xu HY, Ma L, Zhang ZY, Zhao JC, Zhang W, Wei Peng W, Yang G, Yu XY, Xu HT, Yi W. Organo-Se BTSAs-enabled performance: From racemic and asymmetric synthesis to click chemistry application. Chem, 2023; 9:1–12.  （IF19.1，中科院一区）

32. Zhao LP, Rao XN, Zheng RR, Huang C, Kong R, Yu XY#, Cheng H#, Li SY#. Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication.  J Control Release. 2023; 357:460-471. （IF10.5，中科院一区，通讯作者）

33. Liang L, Xu W, Shen A, Fu X, Cen H, Wang S, Lin Z, Zhang L, Lin F, Zhang X, Zhou N, Chang J, Chen ZS, Li C, Yu XY#. Inhibition of YAP1 activity ameliorates acute lung injury through promotion of M2 macrophage polarization. MedComm. 2023; 4(3): e293. （IF10.7，中科院三区，通讯作者）

34. Xu W, Du L, Yu L, Cen H, Lin F, Wang S, Ruan Z, Lin Z, Zhang X, Zhou N, Chang J, Yu XY#, Zhang L#, Liang L#. The mirrored cationic peptide as miRNA vehicle for efficient lung cancer therapy. MedComm. 2023; 4(4):e273. （IF10.7，中科院三区，通讯作者）

35. Lin Z, He H, Xian Y, Cai J, Ge Q, Guo M, Zheng Q, Liu X, Mo C, Zhang X, Qi W, Zhang Y, Liang L, Yu XY#, Zhu YZ#. Discovery of deoxyandrographolide and its novel effect on vascular senescence by targeting HDAC1. MedComm. 2023; 4(5):e338. （IF10.7，中科院三区）

36. Xie J, Wang H, Huang Q, Lin J, Wen H, Miao Y, Lv L, Ruan D, Yu XY, Qin L, Zhou Y. Enhanced cytotoxicity to lung cancer cells by mitochondrial delivery of camptothecin. Eur J Pharm Sci. 2023; 189: 106561. （IF4.3，中科院三区）

37. Zhang DY, Liang Y, Wang M, Younis MR, Yi H, Zhao X, Chang J, Zheng Y, Guo W, Yu XY#. Self-Assembled Carrier-Free Nanodrugs for Starvation Therapy-Amplified Photodynamic Therapy of Cancer. Adv Healthc Mater. 2023；12（20）：e2203177. （IF10.0, 中科院二区，通讯作者）

38. Qin A, Wang XJ, Fu J, Shen A, Huang X, Chen Z, Wu H, Jiang Y, Wang Q, Chen F, Xiang AP, Yu XY#. hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway. Mol Biomed. 2023 Sep 14;4(1):27. doi: 10.1186/s43556-023-00137-z. （IF6.3, 中科院一区，通讯作者）

39. Tang GS, Luo ZY, Lian LM, Guo J, Maharjan S, Garciamendez-Mijares CE, Wang M, Li WL, Zhang ZR, Wang D, Xie MB, Ravanbakhsh H, Zhou CP, Kuang X, Hou YY, Yu XY, Zhang YS. Liquid-embedded (bio)printing of alginate-free, standalone, ultrafine, and ultrathin-walled cannular structures. Proc Natl Acad Sci USA, 2023;120(7):e2206762120. （IF9.4，中科院一区）

40. Fu JJ, Liu CC, Feng GM, Li SP, Yu YY, Du LR, Zhang JY, Zhang Y, Lei XP*, Dai XY*, Yu XY*. Activatable unsaturated liposomes increase lipid peroxide of cell membrane and inhibit tumor growth. Biomaterials Advances, 2023; 147: 213323. doi.org/10.1016/ j.bioadv.2023.213323 （IF5.5, 中科院二区，通讯作者）

41. Jiao LJ#, Liu YH#, Yu XY#, Pan XB#, Zhang Y, Tu JC, Song YH*, Li Y*. Ribosome biogenesis in disease: new players and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):15. doi: 10.1038/s41392-022-01285-4. （IF40.8, 中科院一区，共同第一作者）

42. Zhao LP, Rao XN, Huang CY, Zheng RR, Kong RJ, Chen ZX, Yu XY*, Cheng H*, Li SY*. Epigenetic reprogramming of carrier free photodynamic modulator to activate tumor immunotherapy by EZH2 inhibition. Biomaterials. 2023; 293:121952. doi: 10.1016/j.biomaterials.2022.121952. （IF12.8, 中科院一区，通讯作者）

43. Huang JR, Zhang MH, Chen YJ, Sun YL, Gao ZM, Li ZJ, Zhang GP, Qin Y, Dai XY, Yu XY*, Wu XQ*. Urolithin A ameliorates obesity-induced metabolic cardiomyopathy in mice via mitophagy activation. Acta Pharmacol Sin. 2023; 44(2):321-331. （IF6.9, 中科院一区，通讯作者）

44. Li XB, Rekep M, Tian JH, Wu Q, Chen M, Yang S, Zhang LX, Zhang GP, Qin Y, Yu XY, Xue Q, Liu YH. Luteolin Attenuates Diabetic Myocardial Hypertrophy by Inhibiting Proteasome Activity. Pharmacology, 2023;108(1):47-60. （IF2.9, 中科院四区）

45. Wang M, Liang Y, Liao F, Younis MR, Zheng Y, Zhao X, Yu XY*, Guo W*, Zhang DY*. Iridium Tungstate Nanozyme-Mediated Hypoxic Regulation and Anti-inflammation for Duplex Imaging Guided Photothermal Therapy of Metastatic Breast Tumors. ACS Appl Mater Interfaces. 2022;14(51):56471-56482. doi: 10.1021/acsami.2c14799. （IF8.3, 中科院二区，通讯作者）

46. Liang L, Cen HY, Huang JH, Qin AP, Xu WY, Wang SR, Chen ZJ, Tan L, Zhang QQ, Yu XY*, Yang X*, Zhang LM*. The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy. Mol Cancer. 2022; 21:186(1-19). （IF27.7, 中科院一区，通讯作者）

47. Wu XQ, Huang JR, Tang JY, Sun YL, Zhao GJ, Yan CS, Liu ZH, Yi W, Xu SW*, Yu XY*. Isoginkgetin, a bioactive constituent from Ginkgo Biloba, protects against obesity-induced cardiomyopathy via enhancing Nrf2/ARE signaling. Redox Biology. 2022; 57: 102485(1-13). （IF10.7, 中科院一区，通讯作者）

48. Lei XP, Li Z, Zhong YH, Li SP, Chen JC , Ke YY, Lv A, Huang LJ, Pan QR, Zhao LX, Yang XY, Chen ZS*, Deng QD*, Yu XY*. Gli 1 promotes epithelial-mesenchymal transition and metastasis of non-small cell lung carcinoma by regulating snail transcriptional activity and stability. Acta Pharm Sin B. 2022; 12(10):3877-3890. （IF14.7, 中科院一区，通讯作者）

49. Liu YJ, Kyne M, Wang S, Wang S, Yu XY*, Wang C*.  A User-Friendly Platform for Single-Cell Raman Spectroscopy Analysis. Spectrochim Acta A Mol Biomol Spectrosc. 2022; 282:121686. （IF4.3, 中科院二区，通讯作者）

50. Liang L#, Xu WY#, Shen A#, Cen HY, Chen ZJ, Tan L, Zhang LM, Zhang Y, Fu JJ, Qin AP, Lei XP, Li SP, Qin YY*, Huang JH*, Yu XY*. Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9. Acta Pharmacol Sin. 2022;43(11):2946-2955.doi: 10.1038/s41401-022-00893-8. （IF6.9, 中科院一区，通讯作者）

51. Song H, Zhang J, Liu B, Xu J, Cai B, Yang H, Straube J, Yu XY*, Ma T*. Biological roles of RNA m5C modification and its implications in Cancer immunotherapy. Biomark Res. 2022;10(1):15. doi: 10.1186/s40364-022-00362-8 （IF9.5, 中科院二区，通讯作者）

52. Li G, He H, Zheng G, Jiang W, Du S, Tao H, Xiao T, Zhou D, Ding S, Yu XY, Zhang Y, Shen A. Direct Detection of Pulmonary Fibrosis by Near-Infrared-Responsive Biomimetic Platelets. Int J Nanomedicine. 2022;17:151-162.  （IF6.6, 中科院二区）

53. Yang LY, Lin YS, Zhang J, Huang JH, Qin AP, Miao YL, Wang P, Yu XY*, Wang L*, Zhang LM*. Biomimetic metal-organic frameworks navigated biological bombs for efficient lung cancer therapy. J Colloid Interface Sci. 2022; 625:532-543. （IF9.4，中科院一区，通讯作者）

54. Tao X, He H, Peng J, Xu R, Fu J, Hu Y, Li L, Yang X, Feng X, Zhang C, Zhang L, Yu XY, Shen A, Huang K, Fu Q. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast. Pharmacol Res. 2022; 175:106004. （IF9.1，中科院一区）

55. Huang JQ, Zhao LP, Zhou X, Liu LS, Zheng RR, Deng FA, Liu YB, Yu XY, Li SY, Cheng H. Carrier Free O2-Economizer for Photodynamic Therapy Against Hypoxic Tumor by Inhibiting Cell Respiration. Small. 2022;18(15):e2107467. （IF13.0，中科院一区）

56. Huang XT#, Sun P#, Qin YY#, Wang XJ, Wang MY, Lin YT, Zhou RQ, Hu WH, Liu QF, Yu XY*, Aiping Qin*. Disulfiram attenuated MCMV-Induced pneumonia by inhibition of NF-B/NLRP3 signaling pathway in immunocompromised mice. Int Immunopharmacol. 2022; 103: 108453. （IF4.8, 中科院二区，通讯作者）

57. Lin Z, Deng Q, Fang Q, Li X, Liu X, Wang J, Chen S, Huang X, Yang L, Miao Y, Yu XY*. Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer. J Drug Target, 2022; 30(6): 614-622. （IF4.3，中科院四区，通讯作者）

58. Zhao LP, Zheng RR, Kong RJ, Huang CY, Rao XN, Yang N, Chen AL, Yu XY*, Cheng H*, Li SY*. Self-delivery ternary bioregulators for photodynamic amplified immunotherapy by tumor microenvironment reprogramming. ACS Nano, 2022; 16(1):1182-1197.  （IF15.8，中科院一区，通讯作者）

59. Lin Z, Chang J, Li X, Wang J, Wu X, Liu X, Zhu Y*, Yu XY*.  Association of DNA methylation and transcriptome reveals epigenetic etiology of heart failure. Funct Integr Genomics, 2022 Feb; 22(1):89-112. （IF3.9，，中科院四区，通讯作者）

60. Zhao LP, Chen SY, Zheng RR, Kong RJ, Rao XN, Chen AL, Cheng H*, Zhang DW*, Li SY*, Yu XY*. Self-delivery nanomedicine for glutamine-starvation enhanced photodynamic tumor therapy. Adv Healthc Mater. 2022; 11(3): 2102038. （IF10.0，，中科院二区，通讯作者）

61. Qin YY, Huang XR, Zhang J, Wu W, Chen J, Wan S, Yu XY*, Lan HY*. Neuropeptide Y attenuates cardiac remodeling and deterioration of function following myocardial infarction. Mol Ther. 2022; 30(2):881-897.（IF12.1，中科院一区，通讯作者）

62. Ding F, Lu L, Wu C, Pan X, Liu B, Zhang Y, Wang Y, Wu W, Yan B, Zhang Y, Yu XY, Li Y. circHIPK3 prevents cardiac senescence by acting as a scaffold to recruit ubiquitin ligase to degrade HuR. Theranostics. 2022;12:7550-7566.（IF12.4，中科院一区）

63. Peng QS, Li H, Deng QD, Liang L, Wang F, Lin YS, Yang LY, Zhang Y*, Yu XY*, Zhang LM*. Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer. J Colloid Interface Sci, 2021; 603:319-332. （IF9.4，中科院一区，通讯作者）

64. Zheng CP, Wu AP, Zhai XY, Ji H, Chen ZK, Chen X*, Yu XY*. The cellular immunotherapy of integrated photothermal anti-oxidation Pd-Se nanoparticles in inhibition of the macrophage inflammatory response in rheumatoid arthritis. Acta Pharm Sin B, 2021; 11(7):1993-2003. (IF14.7，中科院一区，通讯作者)

65. Lin Y, Li S, Xiao Z, Chen S, Yang L, Peng Q, Li H, Fu J*, Yu XY*, Zhang L*. Epigenetic inhibition assisted chemotherapeutic treatment of lung cancer based on artificial exosomes. Pharmacol Res. 2021 Sep;171:105787. （IF9.1，中科院二区，通讯作者）

66. Zhou WM, Yan YY, Guo QR, Ji H, Wang H, Xu TT, Makabel B, Pilarsky C, He G*, Yu XY*, Zhang JY*. Microfluidics applications for high-throughput single cell sequencing. J Nanobiotechnology. 2021;19(1):312. （IF10.6，中科院一区，通讯作者）

67. Zhao LP, Zheng RR, Liu LS, Chen XY, Guan RT, Yang N, Chen AL, Yu XY*, Cheng H*, Li SY*. Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy. Biomaterials 2021; 275: 120970. （IF12.8，中科院一区，通讯作者）

68. Li XY, Deng FA, Zheng RR, Liu LS, Liu YB, Kong RJ, Chen AL, Yu XY, Li SY, Cheng H. Carrier Free Photodynamic Synergists for Oxidative Damage Amplified Tumor Therapy. Small. 2021;17(40):e2102470. （IF13.0，中科院二区）

69. Li JX, Zhang LM, Liu CC, Wu QN, Li SP, Lei XP, Huang YG, Feng GN, Yu XY, Sun XQ, Guo ZM, Fu JJ. Doxorubicin-loaded hydrogen peroxide self-providing copper nanodots for combination of chemotherapy and acid-induced chemodynamic therapy against breast cancer. J Colloid Interface Sci. 2021; 593: 323-334. （IF9.4，中科院一区）

70. Zheng RR, Zhao LP, Liu LS, Deng FA, Chen XY, Jiang XY, Wang C, Yu XY*, Cheng H*, Li SY*. Self-delivery nanomedicine to overcome drug resistance for synergistic chemotherapy. Biomater Sci. 2021;9(9):3445-3452. （IF7.6，中科院三区，通讯作者）

71. Deng QD, Lei XP, Zhong YH, Chen MS, Ke YY, Li Z, Chen J, Huang LJ, Zhang Y, Liang L, Lin ZX, Liu Q, Li SP, Yu XY*. Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition. Acta Pharmacol Sin. 2021; 42(9):1486-1497. （IF6.9，中科院一区，通讯作者）

72. Li H, Li SP, Lin YS, Chen S, Yang LY, Huang X, Wang H*, Yu XY*, Zhang LM*. Artificial exosomes mediated spatiotemporal-resolved and targeted delivery of epigenetic inhibitors. J Nanobiotechnology. 2021; 19(1):364. （IF10.6，中科院一区，通讯作者）

73. Wang H, Shi W, Zeng D, Huang Q, Xie J, Wen H, Li J, Yu XY, Qin L, Zhou Y. pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer. J Nanobiotechnology. 2021;19(1):152. （10.6，中科院一区）

74. Zheng RR, Zhao LP, Chen XY, Liu LS, Liu YB, Chen XT, Wang C, Yu XY, Cheng H, Li SY. Metal-coordinated nanomedicine for combined tumor therapy by inducing paraptosis and apoptosis. J Control Release, 2021; 336:159-168. （IF10.5，中科院一区）

75. Yuan P, Deng FA, Liu YB, Zheng RR, Rao XN, Qiu XZ, Zhang DW, Yu XY, Cheng H, Li SY. Mitochondria Targeted O 2 Economizer to Alleviate Tumor Hypoxia for Enhanced Photodynamic Therapy. Advanced Healthcare Materials 2021, 10 (12): 2100198. （IF10.0，中科院二区）

76. Chang JS, Lin ZX, Liu YJ, Yang SM, Zhang Y, Yu XY*. Ultra performance liquid chromatography-tandem mass spectrometry assay for the quantification of RNA and DNA methylation. J Pharm Biomed Anal, 2021;197:113969. （IF3.1，中科院一区，通讯作者）

77. Wu Q, Tian JH, He YX, Huang YY, Huang YQ, Zhang GP, Luo JD, Xue Q*, Yu XY*, Liu YH*. Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin, 2021; 42(10):1587-1597. （IF6.9，中科院一区，通讯作者）

78. Guo QR, Zhang LL, Liu JF, Li Z, Li JJ, Zhou WM, Wang H, Li JQ, Liu DY*, Yu XY*, Zhang JY*. Multifunctional microfluidic chip for cancer diagnosis and treatment. Nanotheranostics. 2021;5(1):73-89. （IF11.560，中科院一区，通讯作者）

79. Zheng R, Chen X, Zhao L, Yang N, Guan R, Chen A, Yu XY, Cheng H, Wang C, Li S. A porphysome-based photodynamic O2 economizer for hypoxic tumor treatment by inhibiting mitochondrial respiration. Chem Commun (Camb). 2021;57(34):4134-4137. （IF4.3，中科院二区）

80. Xiang Zhou, Jia-Qi Huang, Ling-Shan Liu, Fu-An Deng, Yi-Bin Liu, Yan-Mei Li, A-Li Chen, Xi-Yong Yu, Shi-Ying Li, Hong Cheng. Self-Remedied Nanomedicine for Surmounting the Achilles’ Heel of Photodynamic Tumor Therapy. ACS Applied Bio Materials, 2021; 4 (11):8023-8032. （IF4.6）

81. Qin A, Chen S, Wang P, Huang X, Zhang Y, Liang L, Du LR, Lai DH, Ding L, Yu XY*, Xiang AP*. Knockout of NOS2 Promotes Adipogenic Differentiation of Rat MSCs by Enhancing Activation of JAK/STAT3 Signaling. Front Cell Dev Biol. 2021; 9: 638518. （IF4.6，中科院二区，通讯作者）

82. Wang Y, Xie W, Liu B, Huang H, Luo W, Zhang Y, Pan X, Yu XY, Shen Z, Li Y. Stem cell-derived exosomes repair ischemic muscle injury by inhibiting the tumor suppressor Rb1-mediated NLRP3 inflammasome pathway. Signal Transduct Target Ther. 2021; 6(1):121. （IF40.8，中科院一区）

83. Li Y, Huang H, Liu B, Zhang Y, Pan X, Yu XY, Shen Z, Song YH. Inflammasomes as therapeutic targets in human diseases. Signal Transduct Target Ther. 2021; 6(1):247. doi: 10.1038/s41392-021-00650-z. （IF40.8，中科院一区）

84. Wu X, Liu Z, Yu XY*, Xu S, Luo J*. Autophagy and cardiac diseases: Therapeutic potential of natural products. Med Res Rev. 2021; 41(1):314-341.（IF10.9，中科院一区，通讯作者）

85. Meng JX#, Qin YY#, Chen JZ, Wei LH, Huang XR, Yu XY*, Lan HY*. Treatment of Hypertensive Heart Disease by Targeting Smad3 Signaling in Mice. Mol Ther Methods Clin Dev. 2020; 18: 791-802. （IF4.7，中科院二区，通讯作者）

86. Li H, Peng Q, Yang L, Lin Y, Chen S, Qin Y, Li S*, Yu XY*, Zhang L*. High-Performance Dual Combination Therapy for Cancer Treatment with Hybrid Membrane-Camouflaged Mesoporous Silica Gold Nanorods. ACS Appl Mater Inter. 2020;12(52):57732-57745. （IF8.3，中科院二区，通讯作者）

87. Zhao LP, Zheng RR, Huang JQ, Chen XY, Deng FA, Liu YB, Huang CY, Yu XY*, Cheng H*, Li SY*. Self-Delivery Photo-Immune Stimulators for Photodynamic Sensitized Tumor Immunotherapy. ACS Nano, 2020;14(12):17100-17113. （IF15.8，中科院一区，通讯作者）

88. Shao LB, Zhang Y, Pan XB, Liu B, Liang C, Zhang YQ, Wang YL, Yan B, Xie WP, Sun Y, Shen ZY, Yu XY, Li Y. Knockout of beta‑2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell‑induced immune rejection. Cell Mol Life Sci. 2020;77(5):937-952. （IF6.2，中科院二区）

89. Liu YJ, Kyne M, Wang C, Yu XY*. Data mining in Raman imaging in a cellular biological system. Computational and Structural Biotechnology Journal. 2020; 18: 2920–2930. （IF4.4，中科院二区，通讯作者）

90. Liang L, Fu JJ, Wang SR, Cen HY, Zhang LM, Mandukhail SR, Du LR, Wu QN, Zhang PQ, Yu XY*. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. Acta Pharm Sin B, 2020;10(6):1036-1046. （IF14.7，中科院一区，通讯作者）

91. Zhao LP, Zheng RR, Chen HQ, Liu LS, Zhao XY, Liu HH, Qiu XZ, Yu XY*, Cheng H*, Li SY*. Self-Delivery Nanomedicine for O2-economized photodynamic tumor therapy.  Nano Lett. 2020; 20(3):2062-2071. （IF9.6,高被引论文，中科院一区，通讯作者）

92. Zhang L, Deng S, Zhang Y, Peng Q, Li H, Wang P, Fu X, Lei X, Qin A*, Yu XY*. Homotypic Targeting Delivery of siRNA with Artificial Cancer Cells. Advanced Healthcare Materials. 2020; 9(9):e1900772. （IF10.0，中科院二区，通讯作者）

93. Chen MY, Xiao ZK, Lei XP, Li JX, Yu XY, Zhang JY, Ye GD, Guo YJ, Mo GG, Li CW, Zhang Y, Zhang LM, Lin ZQ, Fu JJ*. Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles.  J Nanobiotechnology, 2020; 18: 57. （IF10.6，中科院一区）

94. Wang J, Jiang X, Zhao L, Zuo S, Chen X, Zhang L, Lin Z, Zhao X, Qin Y, Zhou X, Yu XY*. Lineage reprogramming of fibroblasts into induced cardiac progenitor cells by CRISPR/Cas9-based transcriptional activators. Acta Pharmaceutica Sinica B, 2020; 10:313-326. Epub 2019 Sep 17. （IF14.7，中科院一区，通讯作者）

95. Lei XP#, Zhong YH#, Huang LJ, Li SP, Fu JJ, Zhang LM, Zhang Y, Deng QD*, Yu XY*. Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer. Cell Death & Disease. 2020; 11(4):232(1-13). （IF8.1，中科院一区，通讯作者）